Roth/MKM Assumes Chemomab Therapeutics (CMMB) at Buy

Roth/MKM analyst Jason Wittes assumes coverage on Chemomab Therapeutics (NASDAQ: CMMB) with a Buy rating and a price target of $7.00.

The analyst comments "We are resuming coverage of CMMB with a Buy rating and $7 PT. The company has a first-in-class anti-CCL24 monoclonal antibody CM-101 currently in Phase 2 development for the rare disease, primary sclerosing cholangitis (PSC). CCL24 plays a dual role in inflammation and fibrosis disease, thus is applicable to a wide variety of diseases. Topline results for the Phase 2 PSC trial are anticipated for 2H24, but enrollment continues to go well, and the company plans to provide a timing update early next year."

For an analyst ratings summary and ratings history on Chemomab Therapeutics click here. For more ratings news on Chemomab Therapeutics click here.

Shares of Chemomab Therapeutics closed at $0.51 yesterday.

You May Also Be Interested In

• BofA Securities Starts Kanzhun Ltd. (BZ) at Neutral
• Needham Starts Pulse Biosciences (PLSE) at Buy
• Craig-Hallum Starts Horizon Quantum (HQ) at Buy